IL-3 in the clinic

Stem Cells

Volumn 15, Issue 5, 1997, Pages 327-333

  Eder, Matthias ^a   Geissler, Georg ^a   Ganser, Arnold ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Clinical study; Interleukin 3; Therapy

Indexed keywords

ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3;

ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW TRANSPLANTATION; CLINICAL RESEARCH; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; HUMAN; IMMUNOTHERAPY; MYELODYSPLASTIC SYNDROME; REVIEW;

EID: 0030818586     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.150327     Document Type: Review

References (69)

1. Yang YC, Ciarletta AB, Temple PA et al. Human IL-3 (multi CSF): identification by expression cloning of a novel hematopoietic growth factor related to murine IL-3. Cell 1986;47:3-10.
2. Kitamura T, Sato N, Arai K et al. Expression cloning of the human IL-3 receptor cDNA reveals a shared β-subunit for human IL-3 and GM-CSF receptors. Cell 1991;66:1165-1174.
3. Miyajima A, Mui AL-F, Ogorochi T et al. Receptors for granulocyte-macrophage colony-stimulating factor, interleukin-3, and interleukin-5. Blood 1993;82:1960-1974.
4. Stomski FC, Sun Q, Bagley CJ et al. Human interleukin-3 (IL-3) induces disulfide-linked IL-3 receptor alpha-and beta-chain heterodimerization, which is required for receptor activation but not high-affinity binding. Mol Cell Biol 1996;16:3035-3046.
5. Quelle FW, Sato N, Witthuhn BA et al. JAK2 associates with the βc chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal domain. Mol Cell Biol 1994;14:4335-4341.
6. Ihle JN. Cytokine receptor signalling. Nature 1995;377:591-594.
7. Inhorn RC, Carlesso N, Durstin M et al. Identification of a viability domain in the granulocyte-macrophage colony-stimulating factor receptor beta-chain involving tyrosine-750. Proc Natl Acad Sci USA 1995;92:8665-8669.
8. Pratt JC, Weiss M, Sieff CA et al. Evidence for a physical association between the Shc-PTB domain and the beta c chain of the granulocyte-macrophage colony-stimulating factor receptor. J Biol Chem 1996;271:12137-12140.
9. Kitamura T, Miyajima A. Functional reconstitution of the human interleukin-3 receptor. Blood 1992;80:84-90.
10. Park LS, Waldron PE, Friend D et al. Interleukin-3, GM-CSF, and G-CSF receptor expression on cell lines and primary leukemia cells: receptor heterogeneity and relationship to growth factor responsiveness. Blood 1989;74:56-65.
11. Donahue E, Seehra J, Metzger M et al. Human IL-3 and GM-CSF act synergistically in stimulating hematopoiesis in primates. Science 1988;241:1820-1823.
12. Platzer E, Weite K, Gabrilove L et al. Biological activities of a human pluripotent hemopoietic colony stimulating factor on normal and leukemic cells. J Exp Med 1985;162:1788-1801.
13. Leary AG, Yang YC, Clark SC et al. Recombinant gibbon interleukin-3 supports human multi-lineage colonies and blast cell colonies in culture: comparison with recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1987;70:1343.
14. Sieff CA, Niemeyer CM, Nathan DG et al. Stimulation of human hematopoietic colony formation by recombinant gibbon multi-colony-stimulating factor or interleukin-3. J Clin Invest 1987;80:818-823.
15. Valent P, Schmidt G, Besemer J et al. Interleukin-3 is a differentiation factor for human basophils. Blood 1989;73:1763-1769.
16. Saeland S, Caux C, Favre JP et al. Effects of recombinant human interleukin-3 on CD34-enriched hematopoietic progenitors and on myeloblastic leukemia cells. Blood 1988;72:1580-1588.
17. Yonemura Y, Ku H, Hirayama F et al. Interleukin-3 or interleukin-1 abrogates the reconstituting ability of hematopoietic stem cells. Proc Natl Acad Sci USA 1996;93:4040-4044.
18. Peters SO, Kittler EL, Ramshaw HS. Ex vivo expansion of murine marrow cells with interleukin-3 (IL-3), IL-6, IL-11, and stem-cell factor leads to impaired engraftment in irradiated hosts. Blood 1996;87:30-37.
19. Ganser A, Lindemann A, Seipelt G et al.The effect of recombinant human interleukin-3 in patients with normal hemopoiesis and in patients with secondary bone marrow failure. Blood 1990;76:666-676.
20. Ganser A, Seipelt G, Lindemann A et al. Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood 1990;76:455-462.
21. Dunbar CE, Smith D, Kimball J et al. Sequential treatment with recombinant human growth factors to compare activity of GM-CSF and IL-3 in the treatment of primary myelodysplasia. Blood 1990;76(suppl 1):141a.
22. Kurzrock R, Talpaz M, Estrov Z et al. Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol 1991;9:1241-1250.
23. Nimer SD, Pacquette L, Ireland P et al. A phase n study of interleukin-3 in patients with aplastic anemia and myelodysplasia. Exp Hematol 1994;22:875-880.
24. Bernstein SF, Gilliland DG, Aster J et al. A randomized trial of two doses of recombinant interleukin-3 in patients with myelodysplastic syndrome. Blood 1992;80(suppl 1):410a.
25. Ganser A, Ottmann OG, Seipelt G et al. Effects of long-term treatment with recombinant human interleukin-3 in patients with myelodysplastic syndromes. Leukemia 1993;7:696-701.
26. List AL, Noyes W, Power J et al. Combined treatment of myelodysplastic syndromes (MDS) with recombinant human interleukin-3 (IL-3) and erythropoietin (Epo). Blood 1993;82(suppl 1):1491a.
27. Verhoef G, Demunyck H, Zachee P et al. Treatment of myelodysplastic syndromes (MDS) with the combination of interleukin-3 and erythropoietin. Blood 1993;82(suppl 1):1492a.
28. Nand S, Sosman J, Godwin JE et al. A phase I/II study of sequential interleukin-3 and granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes. Blood 1994;833:357-360.
29. Gerhartz HH, Walther J, Neuwirtova R et al. Randomized 3-arm phase III study of interleukin-3 (IL-3) or granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjuvant to low doses of cytosine arabinoside (LD-AraC) for the treatment of high-risk myelodysplastic syndromes (HR-MDS). Blood 1996;88(suppl 1):2309a.
30. Schiffer CA. Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood 1996;88:3675-3685.
31. Brach M, Klein H, Platzer E et al. Effect of Interleukin-3 on cytosine arabinoside-mediated cytotoxicity of leukemic myeloblasts. Exp Hematol 1990;18:748-753.
32. Tafuri A, Lemoli RM, Chen R et al. Combination of hematopoietic growth factors containing IL-3 induce acute myeloid leukemia cell sensitization to cycle specific and cycle non-specific drugs. Leukemia 1994;8:749-757.
33. Smith MA, Singer CR, Pallister CJ et al. The effect of hematopoietic growth factors on the cell cycle of AML progenitors and their sensitivity to cytosine arabinoside in vitro. Br J Haematol 1995;90:767-773.
34. Wielenga JJ, Vellenga E, Groenewegen A et al. Recombinant human interleukin-3 (rh IL-3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): a phase I/II study. Leukemia 1996;10:43-47.
35. Gibson FM, Scopes J, Daly S et al. Haemopoietic growth factor production by normal and aplastic anaemia stroma in long-term bone marrow culture. Br J Haematol 1995;91:551-561.
36. Gibson FM, Scopes J, Daly S et al. In vitro response of normal and aplastic bone marrow to mast cell growth factor and in combination with granuloycte-macrophage colony-stimulating factor and interleukin-3. Exp Hematol 1994;22:302-312.
37. Scopes J, Daly S, Ball SE et al. The effect of human Flt-3 ligand on committed progenitor cell production from normal, aplastic anaemia and Diamond-Blackfan anaemia bone marrow. Br J Haematol 1995;91:544-550.
38. Ganser A, Lindemann A, Seipelt G et al. Effects of recombinant human interleukin-3 in aplastic anemia. Blood 1990;76:1287-1292.
39. Bargetzi MJ, Gluckman E, Tichelli A et al. Recombinant human interleukin-3 in refractory severe aplastic anemia: a phase I/II trial. Br J Haematol 1995;91:306-312.
40. Gillio AP, Castro Malaspina H, Gasparetto C et al. Human recombinant interleukin-3 treatment in patients with myelodysplastic syndrome and aplastic anemia. Blood 1995;78(suppl 1):95a.
41. Raghavachar A, Ganser A, Freund M et al. Long-term interleukin-3 and intense immunosuppression in the treatment of aplastic anemia. Cytokines Molec Therapy 1996;2:215-223.
42. Ball SE, Tchemia G, Wranne L et al. Is there a role for interleukin-3 in Diamond-Blackfan anaemia? Results of a European multicentre study. Br J Haematol 1995;91:313-318.
43. Gillio AP, Faulkner LB, Alter BP et al. Treatment of Diamond-Blackfan anaemia with recombinant human interleukin-3. Blood 1993;82:744-751.
44. Dunbar CE, Smith DA, Kimball J et al. Treatment of Diamond-Blackfan anaemia with haematopoietic growth factors, granulocyte-macrophage colony-stimulating factor and interleukin-3 sustained remission following IL-3. Br J Haematol 1991;79:316-321.
45. Olivieri F, Feig SA, Valentino L et al. Failure of recombinant human interleukin-3 therapy to induce erythropoiesis in patients with refractory Diamond-Blackfan anaemia. Blood 1994;83:2444-2450.
46. +)-selected human peripheral blood progenitor cells. Blood 1994;84:2898-2903.
47. + cells from patients with stage IV breast cancer. Blood 1994;84:3567-3574.
48. Brugger W, Heimfeld S, Berenson RJ et al. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med 1995;333:283-287.
49. Alcorn MJ, Holyoake L, Richmond L et al. CD34-positive cells isolated from cryopreserved peripheral-blood progenitor cells can be expanded ex vivo and used for transplantation with little or no toxicity. J Clin Oncol 1996;14:1839-1847.
50. Prince HM, Imrie K, Sutherland DR et al. Peripheral blood progenitor cell collections in multiple myeloma: predictors and management of inadequate collections. Br J Haematol 1996;93:142-145.
51. Vose JM, Kessinger A, Bierman PJ et al. The use of rhIL-3 for mobilization of peripheral blood stem cells in previously treated patients with lymphoid malignancies. Int J Cell Cloning 1992;10(suppl 1):62-64.
52. Haas R, Ehrhardt R, Witt B et al. Autografting with peripheral blood stem cells mobilized by sequential interleukin-3/granulocyte-macrophage colony-stimulating factor following high-dose chemotherapy in non-Hodgkin's lymphoma. Bone Marrow Transplant 1993;12:643-649.
53. Geissler K, Peschel C, Niederwieser D et al. Potentiation of granulocyte colony-stimulating factor-induced mobilization of circulating progenitor cells by seven-day pretreatment with interleukin-3. Blood 1996;87:2732-2739.
54. Rosenfeld CS, Bolwell B, LeFever A et al. Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and in combination with GM-CSF or G-CSF. Bone Marrow Transplant 1996;17:179-183.
55. Sosman JA, Stiff PJ, Bayer RA et al. A phase I trial of interleukin-3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy. Bone Marrow Transplant 1995;16:655-661.
56. Nemunaitis J, Appelbaum FR, Singer JW et al. Phase I trial with recombinant human interleukin-3 in patients with lymphoma undergoing autologous bone marrow transplantation. Blood 1993;82:3273-3278.
57. Fay JW, Lazarus H, Herzig R et al. Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study. Blood 1994;84:2151-2157.
58. Suttorp M, Schmitz N, Prange E et al. Remission of juvenile chronic myeloid leukemia following graft failure of an unrelated marrow transplant and autologous recovery of marrow function promoted by GM-CSF and IL-3. Leukemia 1991;5:723-725.
59. Vannucchi AM, Bosi A, Lasszlo D et al. Treatment of a delayed graft failure after allogeneic bone marrow transplantation with IL-3 and GM-CSF. Haematologica 1995;80:341-343.
60. deVries EG, van Gameren MM, Willemse PH. Recombinant human interleukin-3 in clinical oncology. STEM CELLS 1993;11:72-80.
61. D'Hondt V, Weynants P, Humblet Y et al. Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy. J Clin Oncol 1993;11:2063-2071.
62. Tepler I, Elias A, Kalish L et al. Effect of recombinant human interleukin-3 on haematologic recovery from chemotherapy-induced myelosuppression. Br J Haematol 1994;87:678-686.
63. Speyer JL, Mandeli J, Hochster H et al. A phase I trial of cyclophosphamide and carboplatinum combined with interleukin-3 in women with advanced-stage ovarian cancer. Gynecol Oncol 1995;56:387-394.
64. Brugger W, Frisch J, Schulz G et al. Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin. J Clin Oncol 1992;10:1452-1459.
65. O'Shaughnessy JA, Venzon DJ, Gossard M et al. A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with LAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy. Blood 1995;86:2913-2921.
66. Younes A, Sarris A, Consoli U et al. A pilot study of high-dose interleukin-3 treatment of relapsed follicular small cleaved-cell lymphoma: hematologic, immunologic, and clinical results. Blood 1996;87:1698-1703.
67. Scadden DT, Levine JD, Bresnahan J et al. In vivo effects of interleukin-3 in HIV type 1-infected patients with cytopenia. AIDS Res Hum Retroviruses 1995;11:731-740.
68. Theodossiou C, Kroog C, Ettinghausen S et al. Acute arterial thrombosis in a patient with breast cancer after chemotherapy with 5-fluorouracil, doxorubicin, leucovorin, cyclophosphamide, and interleukin-3. Cancer 1994;74:2808-2810.
69. Hurwitz N, Probst A, Zufferey G et al. Fatal vascular leak syndrome with extensive hemorrhage, peripheral neuropathy and reactive erythrophagocytosis: an unusual complication of recombinant IL-3 therapy. Leuk Lymphoma 1996;20:337-340.